FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2096691041> ?p ?o ?g. }

• W2096691041 endingPage "1269" @default.
• W2096691041 startingPage "1259" @default.
• W2096691041 abstract "Melanoma, the most deadly form of skin cancer, is aggressive and resistant to current therapies. It has been previously reported that the substance P and neurokinin-1 (NK-1) receptor antagonists induce cell proliferation and cell inhibition, respectively, in human melanoma cell lines. Aprepitant is a selective high-affinity antagonist of the human NK-1 receptor. Until now, this drug has been used as an anxiolytic, antidepressant and antiemetic. Moreover, the antitumor action of aprepitant has been previously reported. However, the presence of NK-1 receptors in human melanomas and whether the antitumor action of the NK-1 receptor antagonist aprepitant is exerted on human malignant melanomas have not been previously described. The aims of this study are to show the presence of NK-1 receptors in human malignant melanomas and the antitumoral action of aprepitant against several human melanoma cell lines. Immunoblot analysis was used to determine the presence of NK-1 receptors in human melanoma cell lines, and immunohistochemistry was used to demonstrate NK-1 receptors in human melanoma samples. We performed an in vitro study of the cytotoxicity of the NK-1 receptor antagonist aprepitant on human melanoma cell lines. A coulter counter was used to determine viable cell numbers, followed by application of the tetrazolium compound MTS. The DAPI method was applied to demonstrate apoptosis. We observed that NK-1 receptors were present in all the melanoma samples studied as well as in human melanoma cell lines. We also showed that melanoma cell lines expressed mRNA for the NK-1 receptor. Moreover, after using a knockdown method, we showed that NK-1 receptors are involved in the viability of tumor cells. In this study, we also report that aprepitant, at 10-60 microM concentrations, elicits cell growth inhibition in a concentration-dependent manner in all melanoma cell lines studied, that the specific antitumor action of aprepitant occurs through the NK-1 receptor and that melanoma cell death is due to apoptosis. These findings show for the first time that the NK-1 receptor may be a promising new target and that the NK-1 receptor antagonist aprepitant could be a candidate as a new antitumor drug in the treatment of human melanoma." @default.
• W2096691041 created "2016-06-24" @default.
• W2096691041 creator A5007827622 @default.
• W2096691041 creator A5017744155 @default.
• W2096691041 creator A5019062658 @default.
• W2096691041 creator A5020163776 @default.
• W2096691041 creator A5057489673 @default.
• W2096691041 creator A5065864417 @default.
• W2096691041 creator A5090666491 @default.
• W2096691041 date "2010-08-01" @default.
• W2096691041 modified "2023-10-14" @default.
• W2096691041 title "The NK-1 receptor is expressed in human melanoma and is involved in the antitumor action of the NK-1 receptor antagonist aprepitant on melanoma cell lines" @default.
• W2096691041 cites W1965871971 @default.
• W2096691041 cites W1969358425 @default.
• W2096691041 cites W1973773456 @default.
• W2096691041 cites W1974412135 @default.
• W2096691041 cites W1978113416 @default.
• W2096691041 cites W1981018090 @default.
• W2096691041 cites W1992694594 @default.
• W2096691041 cites W2005119541 @default.
• W2096691041 cites W2010286023 @default.
• W2096691041 cites W2013736669 @default.
• W2096691041 cites W2020835847 @default.
• W2096691041 cites W2023765572 @default.
• W2096691041 cites W2024339132 @default.
• W2096691041 cites W2026255554 @default.
• W2096691041 cites W2028508823 @default.
• W2096691041 cites W2046952308 @default.
• W2096691041 cites W2053889778 @default.
• W2096691041 cites W2054222308 @default.
• W2096691041 cites W2055948011 @default.
• W2096691041 cites W2057178512 @default.
• W2096691041 cites W2058523849 @default.
• W2096691041 cites W2067747375 @default.
• W2096691041 cites W2071658004 @default.
• W2096691041 cites W2080718357 @default.
• W2096691041 cites W2086397529 @default.
• W2096691041 cites W2102781248 @default.
• W2096691041 cites W2105620605 @default.
• W2096691041 cites W2111711361 @default.
• W2096691041 cites W2111723542 @default.
• W2096691041 cites W2112322278 @default.
• W2096691041 cites W2114643862 @default.
• W2096691041 cites W2130268591 @default.
• W2096691041 cites W2140799285 @default.
• W2096691041 cites W2165157874 @default.
• W2096691041 cites W2169127836 @default.
• W2096691041 cites W4247936073 @default.
• W2096691041 doi "https://doi.org/10.1038/labinvest.2010.92" @default.
• W2096691041 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20458280" @default.
• W2096691041 hasPublicationYear "2010" @default.
• W2096691041 type Work @default.
• W2096691041 sameAs 2096691041 @default.
• W2096691041 citedByCount "76" @default.
• W2096691041 countsByYear W20966910412012 @default.
• W2096691041 countsByYear W20966910412013 @default.
• W2096691041 countsByYear W20966910412014 @default.
• W2096691041 countsByYear W20966910412015 @default.
• W2096691041 countsByYear W20966910412016 @default.
• W2096691041 countsByYear W20966910412017 @default.
• W2096691041 countsByYear W20966910412018 @default.
• W2096691041 countsByYear W20966910412019 @default.
• W2096691041 countsByYear W20966910412020 @default.
• W2096691041 countsByYear W20966910412021 @default.
• W2096691041 countsByYear W20966910412022 @default.
• W2096691041 countsByYear W20966910412023 @default.
• W2096691041 crossrefType "journal-article" @default.
• W2096691041 hasAuthorship W2096691041A5007827622 @default.
• W2096691041 hasAuthorship W2096691041A5017744155 @default.
• W2096691041 hasAuthorship W2096691041A5019062658 @default.
• W2096691041 hasAuthorship W2096691041A5020163776 @default.
• W2096691041 hasAuthorship W2096691041A5057489673 @default.
• W2096691041 hasAuthorship W2096691041A5065864417 @default.
• W2096691041 hasAuthorship W2096691041A5090666491 @default.
• W2096691041 hasBestOaLocation W20966910411 @default.
• W2096691041 hasConcept C118303440 @default.
• W2096691041 hasConcept C126322002 @default.
• W2096691041 hasConcept C137130169 @default.
• W2096691041 hasConcept C170493617 @default.
• W2096691041 hasConcept C2776533618 @default.
• W2096691041 hasConcept C2776694085 @default.
• W2096691041 hasConcept C2777658100 @default.
• W2096691041 hasConcept C2780574406 @default.
• W2096691041 hasConcept C2780884295 @default.
• W2096691041 hasConcept C502942594 @default.
• W2096691041 hasConcept C54355233 @default.
• W2096691041 hasConcept C71924100 @default.
• W2096691041 hasConcept C81885089 @default.
• W2096691041 hasConcept C86803240 @default.
• W2096691041 hasConcept C98274493 @default.
• W2096691041 hasConceptScore W2096691041C118303440 @default.
• W2096691041 hasConceptScore W2096691041C126322002 @default.
• W2096691041 hasConceptScore W2096691041C137130169 @default.
• W2096691041 hasConceptScore W2096691041C170493617 @default.
• W2096691041 hasConceptScore W2096691041C2776533618 @default.
• W2096691041 hasConceptScore W2096691041C2776694085 @default.
• W2096691041 hasConceptScore W2096691041C2777658100 @default.
• W2096691041 hasConceptScore W2096691041C2780574406 @default.

• next